150 related articles for article (PubMed ID: 32974950)
1. Evaluation of the Relationship of Glasdegib Exposure and Safety End Points in Patients With Refractory Solid Tumors and Hematologic Malignancies.
Ruiz-Garcia A; Shaik N; Lin S; Jamieson C; Heuser M; Chan G
J Clin Pharmacol; 2021 Mar; 61(3):349-359. PubMed ID: 32974950
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of glasdegib (PF-04449913), an oral smoothened inhibitor, in Japanese patients with select hematologic malignancies.
Minami Y; Minami H; Miyamoto T; Yoshimoto G; Kobayashi Y; Munakata W; Onishi Y; Kobayashi M; Ikuta M; Chan G; Woolfson A; Ono C; Shaik MN; Fujii Y; Zheng X; Naoe T
Cancer Sci; 2017 Aug; 108(8):1628-1633. PubMed ID: 28556364
[TBL] [Abstract][Full Text] [Related]
3. An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure.
Lin S; Shaik N; Chan G; Cortes JE; Ruiz-Garcia A
Cancer Chemother Pharmacol; 2020 Oct; 86(4):451-459. PubMed ID: 32885274
[TBL] [Abstract][Full Text] [Related]
4. Glasdegib plus low-dose cytarabine for acute myeloid leukemia: Practical considerations from advanced practitioners and pharmacists.
Relias V; McBride A; Newman MJ; Paul S; Saneeymehri S; Stanislaus G; Tobin J; Hoang CJ; Ryan JC; Galinsky I
J Oncol Pharm Pract; 2021 Apr; 27(3):658-672. PubMed ID: 33215562
[TBL] [Abstract][Full Text] [Related]
5. Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS.
Savona MR; Pollyea DA; Stock W; Oehler VG; Schroeder MA; Lancet J; McCloskey J; Kantarjian HM; Ma WW; Shaik MN; Laird AD; Zeremski M; O'Connell A; Chan G; Cortes JE
Clin Cancer Res; 2018 May; 24(10):2294-2303. PubMed ID: 29463550
[No Abstract] [Full Text] [Related]
6. FDA Approval Summary: Glasdegib for Newly Diagnosed Acute Myeloid Leukemia.
Norsworthy KJ; By K; Subramaniam S; Zhuang L; Del Valle PL; Przepiorka D; Shen YL; Sheth CM; Liu C; Leong R; Goldberg KB; Farrell AT; Pazdur R
Clin Cancer Res; 2019 Oct; 25(20):6021-6025. PubMed ID: 31064779
[TBL] [Abstract][Full Text] [Related]
7. Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial.
Heuser M; Smith BD; Fiedler W; Sekeres MA; Montesinos P; Leber B; Merchant A; Papayannidis C; Pérez-Simón JA; Hoang CJ; O'Brien T; Ma WW; Zeremski M; O'Connell A; Chan G; Cortes JE
Ann Hematol; 2021 May; 100(5):1181-1194. PubMed ID: 33740113
[TBL] [Abstract][Full Text] [Related]
8. Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results.
Cortes JE; Douglas Smith B; Wang ES; Merchant A; Oehler VG; Arellano M; DeAngelo DJ; Pollyea DA; Sekeres MA; Robak T; Ma WW; Zeremski M; Naveed Shaik M; Douglas Laird A; O'Connell A; Chan G; Schroeder MA
Am J Hematol; 2018 Nov; 93(11):1301-1310. PubMed ID: 30074259
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the effect of rifampin on the pharmacokinetics of the Smoothened inhibitor glasdegib in healthy volunteers.
Shaik MN; Hee B; Wei H; LaBadie RR
Br J Clin Pharmacol; 2018 Jun; 84(6):1346-1353. PubMed ID: 29488303
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the impact of renal impairment on the pharmacokinetics of glasdegib in otherwise healthy volunteers.
Shaik N; LaBadie RR; Hee B; Chan G
Cancer Chemother Pharmacol; 2021 Feb; 87(2):241-250. PubMed ID: 33388951
[TBL] [Abstract][Full Text] [Related]
11. Glasdegib in combination with low-dose Cytarabine for the outpatient treatment of relapsed or refractory acute myeloid leukemia in unfit patients.
Zucenka A; Maneikis K; Pugaciute B; Ringeleviciute U; Dapkeviciute A; Davainis L; Daukelaite G; Burzdikaite P; Staras V; Griskevicius L
Ann Hematol; 2021 May; 100(5):1195-1202. PubMed ID: 33661333
[TBL] [Abstract][Full Text] [Related]
12. Exposure-response modeling of the effect of glasdegib on cardiac repolarization in patients with cancer.
Fostvedt LK; Shaik N; Martinelli G; Wagner AJ; Ruiz-Garcia A
Expert Rev Clin Pharmacol; 2021 Jul; 14(7):927-935. PubMed ID: 33993815
[TBL] [Abstract][Full Text] [Related]
13. Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials.
Cortes JE; Dombret H; Merchant A; Tauchi T; DiRienzo CG; Sleight B; Zhang X; Leip EP; Shaik N; Bell T; Chan G; Sekeres MA
Future Oncol; 2019 Nov; 15(31):3531-3545. PubMed ID: 31516032
[TBL] [Abstract][Full Text] [Related]
14. Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib.
Gerds AT; Tauchi T; Ritchie E; Deininger M; Jamieson C; Mesa R; Heaney M; Komatsu N; Minami H; Su Y; Shaik N; Zhang X; DiRienzo C; Zeremski M; Chan G; Talpaz M
Leuk Res; 2019 Apr; 79():38-44. PubMed ID: 30849661
[TBL] [Abstract][Full Text] [Related]
15. Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy.
Cortes JE; Heidel FH; Fiedler W; Smith BD; Robak T; Montesinos P; Candoni A; Leber B; Sekeres MA; Pollyea DA; Ferdinand R; Ma WW; O'Brien T; O'Connell A; Chan G; Heuser M
J Hematol Oncol; 2020 Jul; 13(1):92. PubMed ID: 32664995
[TBL] [Abstract][Full Text] [Related]
16. A quality-adjusted survival time without symptoms or toxicities analysis of glasdegib plus low-dose cytarabine versus low-dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy.
Solem CT; Bell TJ; Kwon Y; Cappelleri JC; Johnson C; Bhattacharyya H; Hoang CJ; Cortes JE
Cancer; 2020 Oct; 126(19):4315-4321. PubMed ID: 32697335
[TBL] [Abstract][Full Text] [Related]
17. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome.
Cortes JE; Heidel FH; Hellmann A; Fiedler W; Smith BD; Robak T; Montesinos P; Pollyea DA; DesJardins P; Ottmann O; Ma WW; Shaik MN; Laird AD; Zeremski M; O'Connell A; Chan G; Heuser M
Leukemia; 2019 Feb; 33(2):379-389. PubMed ID: 30555165
[TBL] [Abstract][Full Text] [Related]
18. Absolute Oral Bioavailability of Glasdegib (PF-04449913), a Smoothened Inhibitor, in Randomized Healthy Volunteers.
Shaik N; Hee B; Liang Y; LaBadie RR
Clin Pharmacol Drug Dev; 2019 Oct; 8(7):895-902. PubMed ID: 30977980
[TBL] [Abstract][Full Text] [Related]
19. Glasdegib with intensive/nonintensive chemotherapy in Japanese patients with untreated acute myeloid leukemia or high-risk myelodysplastic syndromes.
Izutsu K; Ubukawa K; Morishita T; Onishi Y; Ishizawa K; Fujii Y; Kimura N; Yokochi M; Naoe T
Cancer Sci; 2024 Apr; 115(4):1250-1260. PubMed ID: 38327103
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and Safety of Glasdegib in Participants With Moderate/Severe Hepatic Impairment: A Phase I, Single-Dose, Matched Case-Control Study.
Masters JC; LaBadie RR; Salageanu J; Li J; Shaik N
Clin Pharmacol Drug Dev; 2021 Jul; 10(7):707-717. PubMed ID: 33356019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
